Human xanthine oxidoreductase (XOR) is a multiple-level regulated enzyme, resulting from
a complicated evolutionary process that assigned it many physiological roles. The main …

Serum uric acid (SUA) is significantly elevated in obesity, gout, type 2 diabetes mellitus, and
the metabolic syndrome and appears to contribute to the renal, cardiovascular and …

Gout is a disorder that manifests as a spectrum of clinical and pathologic features built on a
foundation of an excess body burden of uric acid, manifested in part by hyperuricemia …

Endothelial xanthine oxidoreductase (XOR) together with NAD (P) H oxidase and nitric
oxide (NO) synthase plays a physiologic role in inflammatory signalling, the regulation of NO …

Xanthine oxidoreductase (XOR) could contribute to the pathogenesis of metabolic syndrome
through the oxidative stress and the inflammatory response induced by XOR-derived …

Hyperuricemia and gout, the clinical manifestation of monosodium urate crystal deposition,
are common in patients with chronic kidney disease (CKD). Although the presence of CKD …

The enzyme xanthine oxidoreductase (XOR) catalyses the last step of purine degradation in
the highest uricotelic primates as a rate-limiting enzyme in nucleic acid catabolism. Although …

Background While several studies have reported a link between the presence of gout and
adverse cardiovascular (CV) events in the general population, none has addressed the …

Gout is the most common inflammatory arthritis worldwide. Although effective treatments
exist to eliminate sodium urate crystals and to'cure'the disease, the management of gout is …

Background Gout therapy includes xanthine oxidase inhibitors (XOI) and colchicine, which
have both been associated with decreased cardiovascular risk. However, their effects on …